Hilo Cuffless Blood Pressure Monitoring System: Technology, Clinical Validation, Regulatory Trajectory and Market Dynamics
The Hilo blood pressure monitoring platform represents a pivotal technological advancement in continuous, non-invasive cardiovascular surveillance. Originally established in Neuchâtel, Switzerland, as Aktiia SA, the enterprise emerged from nearly two decades of dedicated micro-engineering research conducted at the Swiss Center for Electronics and Microtechnology (CSEM). Co-founded by Mattia Bertschi and Josep Sola, the organisation pioneered optical pulse wave analysis to derive arterial pressur
Hilo Cuffless Blood Pressure Monitoring System: Technology, Clinical Validation, Regulatory Trajectory and Market DynamicsCorporate Genesis, Rebranding and Capital StructureThe Hilo blood pressure monitoring platform represents a pivotal technological advancement in continuous, non-invasive cardiovascular surveillance. Originally established in Neuchâtel, Switzerland, as Aktiia SA, the enterprise emerged from nearly two decades of dedicated micro-engineering research conducted at the Swiss Center for Electronics and Microtechnology (CSEM). Co-founded by Mattia Bertschi and Josep Sola, the organisation pioneered optical pulse wave analysis to derive arterial pressure dynamics continuously without relying on repetitive inflatable cuff measurements. In May 2025, Aktiia underwent a comprehensive institutional rebranding to become Hilo, a transition timed to support commercial scaling, international market expansion and enterprise platform integration. The organisation’s capital structure has expanded through institutional venture funding. Hilo closed an oversubscribed $42 Million Series B financing round co-led by Earlybird Health and Wellington Partners, with participation from new institutional investors including Kfund and naturalX Health Ventures, alongside existing backers such as Khosla Ventures, redalpine, Molten Ventures, Translink Capital and Verve Ventures. Subsequent extension rounds increased the company’s total raised capital beyond $119 Million. Under the executive leadership of Chief Executive Officer Raghav "Rags" Gupta, Hilo achieved a 76% compound annual revenue growth rate (CAGR) and recorded over 130,000 commercial device sales across global jurisdictions prior to its full commercial entry into the United States market. The operational transition from CSEM micro-engineering research to Aktiia SA, and ultimately to Hilo, illustrates a structural evolution from a specialized biomedical startup to a high-volume digital health infrastructure provider. By integrating continuous physiological signal collection with cloud-based Machine Learning foundation models, Hilo has positioned its platform at the convergence of consumer medical wearables and clinical-grade diagnostics. Technological Architecture and Operational MechanismOptical Blood Pressure Monitoring DynamicsThe technical foundation of the Hilo system centers on its proprietary Optical Blood Pressure Monitoring (OBPM) technology, which operates within a lightweight wristband pod. Unlike traditional sphygmomanometers that depend on mechanical arterial occlusion via inflatable bladders, Hilo utilises reflective photoplethysmography (PPG). Green light-emitting diodes (LEDs) integrated into the underside of the wrist pod illuminate the microvascular bed of the inner wrist. Photosensors capture variations in reflected light intensity that correspond directly to microvascular volume oscillations driven by cardiac ventricular ejection. The underlying software algorithms process these raw PPG signals beyond simple peak detection for heart rate calculation. Hilo’s foundation machine learning model, trained on tens of billions of optical signals and refined against hundreds of millions of clinical calibration points, analyses the complete morphological structure of each pulse wave. The algorithm extracts biophysical features related to arterial compliance, pulse wave velocity, peripheral vascular resistance and reflected wave timing to calculate uncalibrated estimates of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). This optical wave processing flow functions as an integrated pipeline. Subcutaneous photoplethysmography sensors capture raw volumetric waveforms, which are immediately passed to local and cloud-based signal quality filters. Once low-quality signals caused by major motion artifacts are discarded, the foundation machine learning model extracts structural features of pulse morphology. These features are mapped against the user's calibration profile to compute absolute systolic and diastolic blood pressure values approximately 25 to 50 times per day. The Calibration ArchitectureBecause optical PPG sensors measure relative volumetric changes rather than absolute hydrostatic pressure, Hilo incorporates a hybrid calibration architecture. To ground continuous optical estimates in absolute millimetres of mercury (\text{mmHg}), the platform includes an oscillometric upper-arm calibration cuff. During initial setup, and periodically at 30-day intervals, the user performs a seated calibration using the upper-arm cuff. The initialisation algorithm establishes a personalised baseline transfer function that maps the individual’s unique arterial wave features to discrete oscillometric pressure measurements. Periodic recalibration ensures that long-term changes in vascular tone, ambient temperature influences, or biological aging do not cause measurement drift from absolute pressure baselines over extended monitoring windows. Parameter / FeatureSystem SpecificationMeasurement TechnologyReflective Photoplethysmography (PPG) & Pulse Wave Morphology AnalysisCalibration MethodOscillometric Upper-Arm Cuff (Initial & 30-Day Recalibration Cycle)Sampling FrequencyAutomatic continuous background sampling (~25 to 50 readings per 24 hours)Wrist Pod Dimensions8. 5 { mm (thickness)} \times 16 { mm (width)} \times 34 \{ mm (length)}Wrist Strap Fit Range140 { mm} to 210 mm} wrist circumferenceCalibration Cuff Fit Range22 { cm} to 42{ cm} upper-arm circumferenceHardware Weight16 { grams} total (wrist pod and silicone strap combined)Battery Life & ChargingUp to 15 days operational life; full charge in ~90 minutes via magnetic USB podIngress ProtectionIP68 Certified (Water resistant for showering, handwashing, and swimming)Wireless ProtocolsBluetooth Low Energy (BLE 5. 0+)Operating System SupportiOS 16. 0 or later; Android 8. 0 or laterData Security StandardsEnd-to-end encrypted transport, cloud storage, GDPR compliant (EU)Clinical Evidence, Diagnostic Performance and Regulatory ApprovalsISO 81060-2 Validation DataThe diagnostic authority of any automated blood pressure measurement platform depends on validation against international reference standards. Hilo, operating clinically under its validated Aktiia technology foundation, has undergone validation aligned with the International Organisation for Standardisation ANSI/AAMI/ISO 81060-2 guidelines. ISO 81060-2 compliance requires meeting two statistical evaluation criteria:Criterion 1: Evaluates total population bias, requiring the mean error between the test device and reference determinations (double-blinded auscultation or mercury sphygmomanometry) to be within 5. 0 mmHg}, with a standard deviation (SD) of 8. 0 mmHg}. Criterion 2: Evaluates subject-level consistency, requiring the standard deviation of averaged paired differences per subject to meet specified acceptance thresholds based on the overall mean error. Clinical investigations have evaluated the cuffless wrist sensor against invasive intra-arterial catheterisation within intensive care environments. In these studies, optical blood pressure estimation achieved a standard deviation of error of $7. 1 \text{ mmHg}$ for SBP and $2. 9 \text{ mmHg}$ for DBP relative to continuous arterial lines, demonstrating statistical significance ($p European HealthTech, MedTech, Digital Health Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AIcompanies. www. nelsonadvisors. co. ukNelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @https://www. healthcare. digitalNelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today!https://lnkd. in/e5hTp_xbNelson Advisors pride ourselves on our DNA as ‘Founders advising Founders. ’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investmentreturns. www. nelsonadvisors. co. ukNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTMeet Nelson Advisors @ 2026 EventsDigital Health Rewired>March 2026 > Birmingham, UKNHS ConfedExpo>June 2026 > Manchester, UKHLTH Europe>June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare>July 2026, New York, USABits & Pretzels>September 2026, Munich, GermanyWorld Health Summit 2026>October 2026, Berlin, GermanyHealthInvestor Healthcare Summit>October 2026, London, UKHLTH USA 2026>October 2026, USABarclays Health Elevate>October 2026, London, UKWeb Summit 2026>November 2026, Lisbon, PortugalMEDICA 2026>November 2026, Düsseldorf, GermanyVenture Capital World Summit>December 2026 Toronto, CanadaNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AIcompanies. www. nelsonadvisors. co. uk